After Axsome Therapeutics (AXSM) reported that its ACCORD-2 trial in Alzheimer’s disease agitation met its the primary endpoint, but that the ADVANCE-2 trial with AXS-05 did not, Leerink called this “the outcome that we were hoping to avoid” as well as “the one that creates the most confusion going forward.” While Auvelity has a chance to be approved in Alzheimer’s disease agitation with the positive data from ADVANCE-1 along with ACCORD-1 and ACCORD-2, it is unclear how the FDA will view the withdrawal studies, says the analyst, who believes that investors “will be somewhat skeptical of approval,” but maintains an Outperform rating on Axsome shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Analysts see buying opportunity as Axsome slips on mixed Alzheimer’s studies
- Axsome Therapeutics price target raised to $138 from $132 at RBC Capital
- Axsome AXS-05 ADA results supportive of approval, says BofA
- Boeing slips after Jeju Air crash, HashiCorp-IBM draws review: Morning Buzz
- Axsome AXS-05 results in ADA ‘positive,’ drug looks ‘approvable,’ says Truist